Ascendis Pharma A/S (ASND)
NASDAQ·Healthcare·Biotechnology
$222.61
-1.79%
Mkt Cap $14.73B
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Feb 11, 2026 | $292.26M | $344.84M | +17.99% | -$0.06 | -$0.64 | -966.67% | — | — |
| Q4 2025 Nov 12, 2025 | $302.60M | $250.22M | -17.31% | -$0.41 | -$1.17 | -185.37% | — | — |
| Q3 2025 Aug 7, 2025 | $233.12M | $186.09M | -20.17% | -$1.42 | -$0.93 | +34.51% | — | — |
| Q2 2025 May 1, 2025 | $153.48M | $110.67M | -27.89% | -$1.56 | -$1.66 | -6.41% | — | — |
| Q1 2025 Feb 12, 2025 | $125.42M | $180.09M | +43.59% | -$1.20 | -$0.68 | +43.33% | — | — |
| Q4 2024 Nov 14, 2024 | $74.14M | $63.43M | -14.45% | -$1.83 | -$1.81 | +1.15% | — | — |
| Q3 2024 Sep 3, 2024 | $37.58M | $38.71M | +3.01% | -$1.54 | -$2.05 | -33.12% | — | — |
| Q2 2024 May 2, 2024 | $92.36M | $103.02M | +11.54% | -$1.62 | -$2.48 | -53.33% | — | — |
| Q1 2024 Feb 7, 2024 | $111.12M | $151.44M | +36.28% | -$2.19 | -$1.66 | +24.14% | — | — |
| Q4 2023 Nov 7, 2023 | $55.32M | $50.67M | -8.41% | -$2.55 | -$3.08 | -21.01% | — | — |
| Q3 2023 Aug 16, 2023 | — | $51.70M | — | -$3.09 | -$1.54 | +50.19% | — | — |
| Q2 2023 Apr 27, 2023 | $25.78M | $36.52M | +41.63% | -$2.93 | -$2.18 | +25.56% | — | — |
| Q1 2023 Feb 16, 2023 | $22.05M | $24.66M | +11.86% | -$2.74 | -$3.96 | -44.53% | — | — |
| Q4 2022 Nov 2, 2022 | $13.60M | $14.93M | +9.82% | -$2.52 | -$3.05 | -21.03% | — | — |
| Q3 2022 Aug 10, 2022 | $6.01M | $6.44M | +7.27% | -$2.19 | -$1.50 | +31.46% | — | — |
| Q2 2022 May 11, 2022 | $5.25M | $7.55M | +43.76% | -$2.09 | -$2.31 | -10.50% | — | — |
| Q1 2022 Mar 2, 2022 | $3.38M | $5.55M | +64.20% | -$2.57 | -$2.06 | +20.09% | — | — |
| Q4 2021 Nov 10, 2021 | $1.70M | $1.29M | -24.14% | -$2.63 | -$1.69 | +35.81% | — | — |
| Q3 2021 Aug 25, 2021 | $1.30M | $1.21M | -7.03% | -$2.75 | -$3.01 | -9.45% | — | — |
| Q2 2021 May 27, 2021 | $1.19M | $877.43K | -26.55% | -$2.09 | -$1.43 | +31.58% | — | — |